The Latest Breaking News from WBA

Wilder has been working towards a return to the ring later this year, with Robert Helenius the likely opponent, although that has been thrown into question due to a legal battle

Walgreen Boots Alliance’s (WBA) failure to secure the right valuation for its pharmacy chain Boots and consumer goods company No7 Beauty for divesting them made investors concerned. With the company now focusing on accelerating the growth and profitability of these two units, will it be wise to buy the stock…

Beterbiev remains the only active champion with a 100 percent knockout ratio.

Belfast boxer Caoimhin Agyarko returns to action on Saturday night in London

RBC Capital Markets lowered the price target on Walgreens Boots Alliance Inc (NASDAQ:WBA) to $42 (10% upside) from $46 and maintained the Sector Perform rating. The analysts say that WBA posted solid fiscal 3Q22 results slightly ahead of their estimates and consensus on steady execution in the U.S. against a difficult comp and continued…

GRAPHIC IMAGE WARNING: Guillermo Rigondeaux, who has a 20-3-1 record across his illustrious career, suffered horrific facial injuries after a pressure cooker explosion back in March

Joyce stopped Dubois when the pair met in a hotly contested domestic fight back in 2020, but has only been able to fight once since while watching his rival rise up the ranks

Having already forfeited his WBA belt, the Scot has now given up his WBC crown

Taylor first gave up his WBA world title and has now vacated his WBC strap to ensure a rematch with Jack Catterall can take place next

A whale with a lot of money to spend has taken a noticeably bullish stance on Walgreens Boots Alliance. Looking at options history for Walgreens Boots Alliance (NASDAQ:WBA) we detected 10 strange trades.

With analysts forecasting a recession later this year, investors should consider investing in almost recession-proof stocks. To that end, it could be wise to consider investing in drug store operator Walgreens Boots Alliance (WBA) as the demand for drugs remains stable irrespective of the economic conditions. With robust financials and…